AstraZeneca taps microbiome specialist Seres for I-O support

Source: Fierce Biotech, April 2019

AstraZeneca has teamed up with Seres Therapeutics to explore whether microbiome therapeutics can increase the efficacy of cancer immunotherapies. The deal will see AstraZeneca pay $20 million to collaborate with Seres and test SER-401 in combination with its oncology assets.

Seres firmed up its interest in using microbiome therapeutics in immuno-oncology when it teamed up with the MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy to test SER-401 in combination with a checkpoint inhibitor. The collaboration was underpinned by evidence that the gut microbiome influences how patients with melanoma respond to anti-PD-1 drugs.

In AstraZeneca, Seres has found a partner willing to support further explorations of that idea. Seres will receive $20 million from AstraZeneca in three installments over the next two years, plus money to cover research costs it incurs in the course of the collaboration. Shares in Seres rose 25% following news of the deal.

read the original full article

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder